Professor Janet Dunn

Janet Dunn

TITLE   

Professor of Clinical Trials and Head of Cancer Trials Deputy Director WMS Clinical Trials Unit

CONTACT   

Clinical Trials Unit
Room T1.02
Warwick Clinical Trials Unit
The University of Warwick
Gibbett Hill Campus
Coventry
CV4 7AL 		Tel: 75847
Email: J.A.Dunn@warwick.ac.uk

 

BACKGROUND


Professor Janet Dunn is the Deputy Director of Warwick Clinical Trials Unit (CTU) and Head of Cancer Trials at Warwick Medical School, University of Warwick. She has over 23 years clinical trials experience. She qualified with a BSc (2i) in Mathematical Sciences in 1987, an MSc in Applied Statistics in 1989 from Manchester and gained a PhD in Medicine in 2004 from Birmingham. She started as a junior statistician in 1988 at the Cancer Research UK Clinical Trials Unit, University of Birmingham, working up to Deputy Director and then Assistant Director responsible for over 25 phase III multi-centre randomised clinical trials. She was instrumental in establishing Birmingham as one of the initial 6 national accredited cancer clinical trials units. In 2003 she was awarded a USA National Cancer Institute fellowship which involved a 6 month sabbatical at Washington DC assessing smoking as a risk factor for pancreatic cancer. She is involved in National Cancer Research Institute (NCRI) breast, colorectal, pancreatic, myeloma, melanoma, and head & neck cancer trials and is currently on the NCRI breast cancer clinical studies group. In January 2006 she was appointed as Professor of Clinical Trials at Warwick and was instrumental in establishing cancer trials. Warwick CTU gained full UKCRN registration in 2008 and moved into their new building in 2009 having secured money from Advantage West Midlands Science City and the Wolfson Foundation. Her research interests include the evaluation of prognostic and predictive factors in cancer clinical trials, and designing clinical trials to impact on clinical practice. The establishment of the National Cancer Research Network and the continued funding from Cancer Research UK has resulted in the completion of many successful UK academic trials which have challenged and changed clinical practice. In 2008 Professor Dunn was awarded National Institute of Health Research Senior Investigator status being one of the inaugural cohort of investigators contributing to applied patient centered research. She has been successful in attracting NIHR National Coordinating Centre for Health Technology Assessment (NCCHTA) grants totallling £6 million for cancer trials at Warwick.

CURRENT RESEARCH PROJECTS


  • ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension, with Mr Adrian Willis - Clinical Trials Unit Dr Louise Hiller - Clinical Trials Unit, Funded by: University of Cambridge, Project Start Date: 01/07/2011 Project End Date: 31/12/2018
  • Support for WMS Clinical Trials Unit Facility, Funded by: Wolfson Foundation, Project Start Date: 01/07/2007 Project End Date: 30/06/2017
  • CRUK funded via Cambridge: AVAST-M - Extension, with Dr Andrea Marshall - Health Sciences Research Institute, Funded by: University of Cambridge, Project Start Date: 01/08/2010 Project End Date: 31/07/2016
  • AVAST-M extension - Avastin in advanced melanoma cancer patients. NCRI melanoma clinical studies group trial, Funded by: CRUK, Project Start Date: 01/06/2010 Project End Date: 31/05/2016
  • TEAMM - Tackling early mortality in myeloma, Funded by: NIHR HTA, Project Start Date: 01/06/2010 Project End Date: 31/05/2015
  • Improving breast cancer detection rates through understanding and modelling the patterns of radiologist performance, with Professor Aileen Clarke - Health Sciences Research Institute Professor Nigel Stallard - Health Sciences Research Institute Dr Sian Taylor-Phillips - Health Sciences Research Institute Dr Melina A Kunar - Psychology Professor Stewart L Robinson - WBS - ORMS, Funded by: Breast Cancer Campaign, Project Start Date: 01/10/2011 Project End Date: 30/09/2014
  • Lugols - assessing the role of iodine in head and neck surgery., with Jim McCaul, Funded by: CRUK, Project Start Date: 01/06/2010 Project End Date: 31/05/2014
  • Variation: ATRemis:Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER2 negative breast cancer, Funded by: Cancer Research UK, Project Start Date: 20/04/2011 Project End Date: 31/12/2013
  • ARTemis: Avastin Randomised Trial with neo-adjuvent cheMotherapy for patients with early HER 2 negatIve breaSt cancer, Funded by: Cancer Research UK, Project Start Date: 01/12/2008 Project End Date: 30/11/2013
  • Statistical analysis agreement for ARTIST, Funded by: Unknown, Project Start Date: 01/08/2009 Project End Date: 31/07/2013
  • PET-NECK: Positron emission tomography - CT scan (pet-CT) guided watch and wait policy versus planned neck dissection for locally advanced (N2/N3) nodal metastases in patient with head and neck squamous carcinoma treated with radical chemoradiotherapy., Funded by: NHS NCCHTA, Project Start Date: 01/04/2007 Project End Date: 31/03/2013
  • Supplement from Cambridge University - PERSEPHONE Trial, Funded by: University of Cambridge, Project Start Date: 20/04/2011 Project End Date: 31/03/2013
  • PERSEPHONE: Duration of Trastuzumab study with chemotherapy in early breast cancer: 6 vs 12 months , Funded by: NCCHTA, Project Start Date: 01/04/2007 Project End Date: 28/02/2013
  • MRC DPFS via Queens University Belfast: Identifying markers of response to anti-oestrogen therapy, with Dr Andrea Marshall - Health Sciences Research Institute, Funded by: MRC, Project Start Date: 01/02/2011 Project End Date: 31/01/2013
  • COUGAR 2 Extension - Andrea Marshall, with Dr Andrea Marshall - Health Sciences Research Institute, Funded by: Cancer Research UK, Project Start Date: 01/11/2010 Project End Date: 31/10/2012
  • Sponsorship agreement for clinical research fellowship, Funded by: University Hospitals Coventry and Warwickshire NHS Trust, Project Start Date: 01/08/2009 Project End Date: 30/09/2012
  • West Mids SHA Research Training Fellowship:How does contemporary health care meet the needs of those living with a poor prognostic cancer and does it need improving?, with Miss Claire E Balmer, Health Sciences Research Institute, Dr Frances E Griffiths - Health Sciences Research Institute Prof Janet A Dunn - Health Sciences Research Institute, Funded by: West Midlands Strategic Health Authority, Project Start Date: 01/10/2009 Project End Date: 30/09/2012
  • Data sharing agreement NEAT/TANGO/NRO-TANGO, Funded by: University of Cambridge, Project Start Date: 01/10/2009 Project End Date: 30/09/2012
  • VICTOR (aduvant colorectal trial of COX-2 inhibitors), with Joint Birmingham/Oxford Collaboration/Warwick, Funded by: Merk Educational Grant, Project Start Date: 01/07/2002 Project End Date: 01/07/2012

    View all Research Projects

SELECTED PUBLICATIONS


  • Ishak K, Caro J, Drayson M, Dimopoulos M, Weber D, Augustson B, Child A, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G.(2011) 'Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.' Value In Health 14 672 - 678 (1098-3015)
  • Bartlett, J. M. S., Munro, A. F., Dunn, J. A., McConkey, C., Jordan, S., Twelves, C. J., Cameron, D. A., Thomas, J., Campbell, F. M., Rea, D. W., Provenzano, E., Caldas, C., Pharoah, P., Hiller, L., Earl, H. and Poole C. J.(2010) 'Predictive markers of anthracycline benefit: a prospectively planned analsys of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)' Lancet Oncology, The 11 (3), 266 - 274 (1470-2045)
  • Iqbal, G., Gumber, A., Johnson, M. R. D., Szczepura, A., Wilson, S., Dunn, J. A.(2009) 'Improving ethnicity data collection for health statistics in the UK' 6 (4), 267 - 285 (0732-183X) [article]
  • Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R. and Neoptolemos, J. P.(2009) 'Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer' Journal Of Clinical Oncology 27 (33), 5513 - 5518 (0732-183X) [article]
  • Earl, H. M., Hiller, L., Dunn, J. A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O' Reilly, S., Rea, D. W., Spooner, D. and Poole, C. J., on behalf of the NEAT Investigators(2008) 'NEAT: National Epirubicin Adjuvant Trial ? toxicity, delivered dose intensity and quality of life' British Journal Of Cancer 99 (8), 1226 - 1231 (0007-0920)

View all Publications

Conferences

Update My Profile on the Warwick eRA Portal My Profile last updated: 02/02/2012